Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis

[1]  Michael F. Green,et al.  Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. , 2011, The American journal of psychiatry.

[2]  K. Browman,et al.  In Vivo Pharmacological Characterization of a Novel Selective α7 Neuronal Nicotinic Acetylcholine Receptor Agonist ABT-107: Preclinical Considerations in Alzheimer's Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.

[3]  C. Briggs,et al.  In Vitro Pharmacological Characterization of a Novel Selective α7 Neuronal Nicotinic Acetylcholine Receptor Agonist ABT-107 , 2010, Journal of Pharmacology and Experimental Therapeutics.

[4]  Mark R Bowlby,et al.  A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. , 2009, Pharmacology & therapeutics.

[5]  W. Maier,et al.  Impaired Sensorimotor Gating of the Acoustic Startle Response in the Prodrome of Schizophrenia , 2008, Biological Psychiatry.

[6]  J. Waring,et al.  Preclinical Characterization of A‐582941: A Novel α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition‐Enhancing Properties , 2008, CNS neuroscience & therapeutics.

[7]  Yuko Fujita,et al.  Phencyclidine-Induced Cognitive Deficits in Mice Are Improved by Subsequent Subchronic Administration of the Novel Selective α7 Nicotinic Receptor Agonist SSR180711 , 2008, Biological Psychiatry.

[8]  Edward D Levin,et al.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. , 2007, Biochemical pharmacology.

[9]  A. Olincy,et al.  Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men , 2007 .

[10]  J. Sullivan,et al.  Broad-Spectrum Efficacy across Cognitive Domains by α7 Nicotinic Acetylcholine Receptor Agonism Correlates with Activation of ERK1/2 and CREB Phosphorylation Pathways , 2007, The Journal of Neuroscience.

[11]  Jonathan M. Meyer.  Antipsychotic safety and efficacy concerns. , 2007, The Journal of clinical psychiatry.

[12]  G. Griebel,et al.  SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia , 2007, Neuropsychopharmacology.

[13]  Robert Freedman,et al.  Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia , 2006 .

[14]  W. Maier,et al.  Sensorimotor Gating and Habituation of the Startle Response in Schizophrenic Patients Randomly Treated With Amisulpride or Olanzapine , 2006, Biological Psychiatry.

[15]  R. Hurst,et al.  The Selective α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide Hydrochloride] Enhances GABAergic Synaptic Activity in Brain Slices and Restores Auditory Gating Deficits in Anesthetized Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[16]  E. Wong,et al.  Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. , 2005, Journal of medicinal chemistry.

[17]  D. Hoffman,et al.  Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability , 1995, Psychopharmacology.

[18]  A. Grace,et al.  Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. , 2005, Schizophrenia bulletin.

[19]  J. Hagan,et al.  Predicting drug efficacy for cognitive deficits in schizophrenia. , 2005, Schizophrenia bulletin.

[20]  M. Geyer,et al.  Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects , 2004, Psychopharmacology.

[21]  Robert Freedman,et al.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia , 2004, Psychopharmacology.

[22]  M. Geyer,et al.  Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia , 2003, Biological Psychiatry.

[23]  R. Freedman,et al.  Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism , 2003, Psychopharmacology.

[24]  F. Tarazi,et al.  Effects of Newer Antipsychotics on Extrapyramidal Function , 2002, CNS Drugs.

[25]  R. Freedman,et al.  Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice , 2001, Biological Psychiatry.

[26]  J. Rotrosen,et al.  Impaired prepulse inhibition of acoustic startle in schizophrenia , 2000, Biological Psychiatry.

[27]  T. Sharma,et al.  Normalization of information processing deficits in schizophrenia with clozapine. , 1999, The American journal of psychiatry.

[28]  A. Cools,et al.  Sensory gating in rats: lack of correlation between auditory evoked potential gating and prepulse inhibition. , 1999, Schizophrenia bulletin.

[29]  R. Freedman,et al.  Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice , 1998, Psychopharmacology.

[30]  R. Hitzemann,et al.  Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition , 1997, Psychopharmacology.

[31]  L Kruglyak,et al.  Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Freedman,et al.  Decreased numbers of hipocampal nicotinic receptors in schizophrenia , 1994, Biological Psychiatry.

[33]  C. Grillon,et al.  Startle gating deficits occur across prepulse intensities in schizophrenic patients , 1992, Biological Psychiatry.

[34]  C. De.  Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. , 1991 .

[35]  D. Casey.  Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. , 1991, Psychopharmacology bulletin.

[36]  D L Braff,et al.  Sensorimotor gating and schizophrenia. Human and animal model studies. , 1990, Archives of general psychiatry.

[37]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[38]  W. Klemm.  Neuroleptic-induced catalepsy: A D2 blockade phenomenon? , 1985, Pharmacology Biochemistry and Behavior.

[39]  J. Arnt,et al.  Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics. , 1981, European journal of pharmacology.